Last reviewed · How we verify
Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients (ROSUBREAST)
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based chemotherapy. A total of 400 participants will be randomly assigned to receive either rosuvastatin or placebo for 12 months. The main goal is to determine whether rosuvastatin can prevent cancer treatment-related cardiac dysfunction (CTRCD), defined as a significant drop in heart pumping function. The study will also assess changes in cardiac strain, blood biomarkers, symptoms of heart failure, quality of life, and possible side effects.
Details
| Lead sponsor | Shiraz University of Medical Sciences |
|---|---|
| Phase | PHASE4 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 400 |
| Start date | Sun Feb 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Apr 21 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Anthracycline-induced Cardiac Toxicity
- Breast Cancer
- Anthracycline Related Cardiotoxicity in Breast Cancer
- Anthracycline-induced Cardiotoxicity
Interventions
- Rosuvastatin 20 mg/day
- Placebo tablets similar to rosuvastatin 20mg tablets
Countries
Iran